4D Molecular Therapeutics reported earnings of -$ 1.08 per FDMT share on Nov 12, 2026, beating analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 1.05 |
| Earnings Per Share (Surprise) | -$ 1.08 (-$ 0.03) |
| Last Year's EPS | -$ 0.60 |
| EPS YoY Change |
Out of the last 35 earnings reporting periods, 4D Molecular Therapeutics beat analysts’ expectations 9 times and fell short of expectations 13 time(s). 4D Molecular Therapeutics reported earnings per share of -$ 1.08 in the last report falling to reach an estimated EPS of -$ 1.05 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 1.05 | -$ 1.08 | -$ 1.01 | |
| Aug 13, 2026 | -$ 1.02 | -$ 1.04 | -$ 0.98 | |
| May 7, 2026 | -$ 0.97 | -$ 1.01 | -$ 0.86 | |
| Mar 18, 2026 | -$ 0.53 | $ 0.43 | -$ 0.90 | |
| Nov 10, 2025 | -$ 1.02 | -$ 1.01 | -$ 0.79 | |
| Aug 11, 2025 | -$ 0.88 | -$ 0.98 | -$ 0.63 | |
| May 8, 2025 | -$ 0.84 | -$ 0.86 | -$ 0.66 | |
| Feb 28, 2025 | -$ 0.80 | -$ 0.90 | -$ 0.77 | |
| Nov 13, 2024 | -$ 0.67 | -$ 0.79 | -$ 0.24 | |
| Aug 8, 2024 | -$ 0.72 | -$ 0.63 | -$ 0.77 | |
| May 9, 2024 | -$ 0.73 | -$ 0.66 | -$ 0.88 | |
| Feb 29, 2024 | -$ 0.68 | -$ 0.77 | -$ 0.84 | |
| Nov 9, 2023 | -$ 0.67 | -$ 0.24 | -$ 0.79 | |
| Aug 9, 2023 | -$ 0.77 | -$ 0.77 | -$ 0.87 | |
| May 10, 2023 | -$ 0.88 | -$ 0.88 | -$ 0.82 | |
| Mar 15, 2023 | -$ 0.75 | -$ 0.84 | -$ 0.85 | |
| Nov 8, 2022 | -$ 0.85 | -$ 0.79 | -$ 0.82 | |
| Aug 11, 2022 | -$ 0.78 | -$ 0.87 | -$ 0.28 | |
| May 12, 2022 | -$ 0.73 | -$ 0.82 | -$ 0.61 | |
| Mar 28, 2022 | -$ 0.82 | -$ 0.85 | -$ 2.36 |
4D Molecular Therapeutics’s stock was trading at $ 12.99 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, FDMT’s price decreased to $ 12.23 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 1.08 | $ 12.99 | $ 12.23 | |
| Aug 13, 2026 | -$ 1.04 | $ 11.87 | $ 12.19 | |
| May 7, 2026 | -$ 1.01 | $ 10.42 | $ 10.14 | |
| Mar 18, 2026 | $ 0.43 | $ 8.61 | $ 8.98 | |
| Nov 10, 2025 | -$ 1.01 | $ 10.50 | $ 10.80 | |
| Aug 11, 2025 | -$ 0.98 | $ 5.63 | $ 6.15 | |
| May 8, 2025 | -$ 0.86 | $ 3.12 | $ 3.08 | |
| Feb 28, 2025 | -$ 0.90 | $ 4.48 | $ 4.14 | |
| Nov 13, 2024 | -$ 0.79 | $ 7.87 | $ 8.02 | |
| Aug 8, 2024 | -$ 0.63 | $ 14.71 | $ 14.80 | |
| May 9, 2024 | -$ 0.66 | $ 26.33 | $ 25.70 | |
| Feb 29, 2024 | -$ 0.77 | $ 27.89 | $ 29.37 | |
| Nov 9, 2023 | -$ 0.24 | $ 10.85 | $ 11.05 | |
| Aug 9, 2023 | -$ 0.77 | $ 16.92 | $ 16.65 | |
| May 10, 2023 | -$ 0.88 | $ 17.33 | $ 16.90 | |
| Mar 15, 2023 | -$ 0.84 | $ 18.49 | $ 18.36 | |
| Nov 8, 2022 | -$ 0.79 | $ 8.32 | $ 8.63 | |
| Aug 11, 2022 | -$ 0.87 | $ 10.65 | $ 9.54 | |
| May 12, 2022 | -$ 0.82 | $ 9.30 | $ 9.01 | |
| Mar 28, 2022 | -$ 0.85 | $ 15.13 | $ 16.35 |
4D Molecular Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
4D Molecular Therapeutics missed analysts’ expectations during the last earnings period by
